Outcomes
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-Cel . | SOC . | Tisa-Cel . | SOC . | Liso-Cel . | SOC . | |
| Received bridging corticosteroids (%) | 36 | — | — | — | — | — |
| Received bridging chemotherapy (%) | 0 | — | 83 | — | 63 | — |
| Received >1 SOC chemotherapy regimen (%) | — | 0 | — | 54 | — | 0 |
| Received intended CAR T cell (%) | 94 | — | 96 | — | 97.8 | — |
| Median time to CAR T-cell infusion in days, (interquartile range* or range†) | 29 (27-34)* | — | 52 (31-135)† | — | NR | — |
| Received intended ASCT (%) | — | 36 | — | 32.5 | — | 45.6 |
| Crossover pn protocol (%) | — | — | — | 51 | — | 51 |
| Received cellular therapy off protocol (%) | — | 56 | — | — | — | |
| Follow up, median in months | 24.9 | 10 | 6.2 | |||
| ORR/CR rate (%) | 83/65 | 50/32 | 46/28 | 43 /28 | 86/66 | 48/39 |
| EFS, median in months | 8.3 | 2 | 3 | 3 | 10.1 | 2.3 |
| EFS, % (timepoint in months) | 41 (24 mo) | 16 (24 mo) | NR | NR | 63 (6 mo) | 33 (6 mo) |
| EFS HR (95% CI) | 0.4 (0.31-0.51) | 1.07 (0.82-1.4) | 0.35 (0.23-0.53) | |||
| PFS, median in months | 14.7 | 3.7 | NR | NR | 14.8 | 5.7 |
| PFS HR (95% CI) | 0.49 (0.37-0.65) | NR | 0.406 (0.21-0.66) | |||
| OS, median in months | NE | 25.7 | 16.9 | 15.3 | NE | 16.4 |
| OS HR (95% CI) | 0.708 (0.515-0.972)‡ | NR | 0.51 (0.26-1.004) | |||
| . | ZUMA-7 . | Belinda . | Transform . | |||
|---|---|---|---|---|---|---|
| Axi-Cel . | SOC . | Tisa-Cel . | SOC . | Liso-Cel . | SOC . | |
| Received bridging corticosteroids (%) | 36 | — | — | — | — | — |
| Received bridging chemotherapy (%) | 0 | — | 83 | — | 63 | — |
| Received >1 SOC chemotherapy regimen (%) | — | 0 | — | 54 | — | 0 |
| Received intended CAR T cell (%) | 94 | — | 96 | — | 97.8 | — |
| Median time to CAR T-cell infusion in days, (interquartile range* or range†) | 29 (27-34)* | — | 52 (31-135)† | — | NR | — |
| Received intended ASCT (%) | — | 36 | — | 32.5 | — | 45.6 |
| Crossover pn protocol (%) | — | — | — | 51 | — | 51 |
| Received cellular therapy off protocol (%) | — | 56 | — | — | — | |
| Follow up, median in months | 24.9 | 10 | 6.2 | |||
| ORR/CR rate (%) | 83/65 | 50/32 | 46/28 | 43 /28 | 86/66 | 48/39 |
| EFS, median in months | 8.3 | 2 | 3 | 3 | 10.1 | 2.3 |
| EFS, % (timepoint in months) | 41 (24 mo) | 16 (24 mo) | NR | NR | 63 (6 mo) | 33 (6 mo) |
| EFS HR (95% CI) | 0.4 (0.31-0.51) | 1.07 (0.82-1.4) | 0.35 (0.23-0.53) | |||
| PFS, median in months | 14.7 | 3.7 | NR | NR | 14.8 | 5.7 |
| PFS HR (95% CI) | 0.49 (0.37-0.65) | NR | 0.406 (0.21-0.66) | |||
| OS, median in months | NE | 25.7 | 16.9 | 15.3 | NE | 16.4 |
| OS HR (95% CI) | 0.708 (0.515-0.972)‡ | NR | 0.51 (0.26-1.004) | |||